PCR Technologies Market worth $21.43 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets forecasts the global PCR technologies market to grow from $15.55 billion in 2026 to $21.43 billion by 2031, a 6.6% CAGR. Digital PCR is expected to be the fastest-growing segment at a 9.5% CAGR, supported by demand for molecular diagnostics, genomics, point-of-care testing, and automated workflows. Reagents and consumables represented 65% of the market in 2025, while diagnostic laboratories remained the largest end-user group; industry participants are also expanding digital-PCR capabilities through partnerships and acquisitions.

Analysis

This is not a near-term earnings catalyst for diversified life-science platforms: mid-single-digit category growth is broadly consistent with a mature, post-pandemic molecular-diagnostics market and is unlikely to change consensus estimates for TMO, DHR, RHHBY/Roche or ABT. The investable distinction is mix. Recurring assay and consumable pull-through supports gross-margin durability, but instrument placement can be promotional as vendors compete to build installed base; therefore, reported organic growth without consumables growth or utilization data should not command a higher multiple.

QGEN and BIO have the clearest potential for relative upside if digital-PCR adoption converts from research use into regulated oncology and minimal-residual-disease workflows. QGEN's installed-base strategy could create a higher-quality annuity stream, while BIO's portfolio expansion raises strategic value but also execution risk: acquisition-led digital-PCR growth must exceed dilution, integration costs and any cannibalization of conventional qPCR. The more important competitive threat is not another PCR vendor but NGS displacement in broad genomic panels; PCR wins where turnaround time, cost per answer and decentralized workflow matter, while sequencing captures expanding-content testing.

Over the next 1-3 months, treat this release as a screening prompt rather than a standalone catalyst. Monitor quarterly instrument placements, reagent pull-through, clinical versus research revenue, oncology assay menus and regulatory clearances. Over 6-18 months, a sustained shift toward distributed oncology testing and point-of-care molecular workflows would favor QGEN, BIO and Cepheid exposure within DHR, but reimbursement pressure or weak laboratory volumes would expose the operating leverage embedded in premium-growth assumptions.

Contrarian view: the market may over-credit digital PCR as a new growth leg before clinical reimbursement and assay-menu breadth are proven. A high-growth subsegment can remain too small to move consolidated revenue, particularly for TMO and DHR. The thesis is falsified if QGEN and BIO fail to deliver accelerating consumables growth and management attributes growth primarily to instrument shipments, or if NGS pricing declines enough to narrow PCR's cost-and-speed advantage.

Key Decisions for Investors

• Maintain a 6-12 month relative long QGEN / short TMO basket, sized modestly: QGEN offers greater earnings sensitivity to successful digital-PCR and oncology menu adoption, whereas TMO's scale makes category growth less material. Reassess after the next two earnings prints; exit if QGEN consumables growth does not accelerate or gross margin compresses materially.
• Place BIO on an event-driven watchlist rather than buying the press-release theme. Initiate only after evidence that digital-PCR revenue and consumable pull-through offset integration expense; the key missing data are acquired-platform revenue contribution, recurring-revenue mix and updated synergy guidance.
• For diversified exposure, prefer DHR over ABT/BDX for molecular-diagnostics optionality over 6-18 months, but do not expect PCR alone to move the stock. Use any incremental position only if Cepheid menu expansion and non-respiratory testing utilization are disclosed as organic-growth contributors.
• Avoid chasing ONT on the premise that PCR-market growth automatically benefits sequencing. Consider ONT only if clinical sequencing adoption expands without evidence of low-cost PCR substitution; falling sequencing cost per sample is a direct risk to the PCR premium-workflow thesis.
• Set a quarterly alert for reimbursement decisions and regulatory clearances in blood-based MRD and multiplex oncology assays. Positive coverage is the catalyst that converts technology adoption into recurring clinical test volume; unfavorable coverage would invalidate the highest-multiple digital-PCR cases.